Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer

Current Medicinal Chemistry

Volumn 16, Issue 30, 2009, Pages 3919-3930

  Rossi, A ^a   Maione, P ^a   Ferrara, M L ^b   Sacco, P C ^a   Schettino, C ^a   Bareschino, M A ^a   Gridelli, C ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

ASA404; Bevacizumab; NSCLC; Sorafenib; Sunitinib; Vascular disrupting agents; VEGF Trap; ZD6474

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ABT 571; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; SORAFENIB; SU 012662; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ENZYME ACTIVITY; FATIGUE; HEART DISEASE; HEMOPTYSIS; HUMAN; HYPERTENSION; ILEUS; LUNG DISEASE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; NEUTROPENIA; NONCARDIAC CHEST PAIN; NONHUMAN; PAIN; PATIENT CARE; PROTEIN FUNCTION; PROTEINURIA; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VOMITING;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 70450173465     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789352286     Document Type: Review

References (91)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA. Cancer J. Clin., 2009, 59, 225-249.
2. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA. Cancer J. Clin., 2005, 55, 74-108.
3. Breathnach, O.S.; Freidlin, B.; Conley, B.; Green, M.R.; Johnson, D.H.; Gandara, D.R.; O'Connel, M.; Shepherd, F.A.; Johnson, B.E. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol., 2001, 19, 1734-1742. (Pubitemid 32230875)
4. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 2002, 346, 92-98. (Pubitemid 34438899)
5. Scagliotti, G.V.; Parikh, P.; von Pawel, J.; Biesma, B.; Vansteenkiste, J.; Manegold, C.; Serwatowski, P.; Gatzemeier, U.; Digumarti, R.; Zukin, M.; Lee, J.S.; Mellemgaard, A.; Park, K.; Patil, S.; Rolski, J.; Goksel, T.; de Marinis, F.; Simms, L.; Sugarman, K.P.; Gandara, D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 3543-3551.
6. Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 2003, 3, 401-410.
7. Hicklin, D.J.; Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 2005, 23, 1011-1027. (Pubitemid 46202320)
8. Ushijima, C.; Tsukamoto, S.; Yamazaki, K.; Yoshino, I.; Sugio, K.; Sugimachi, K. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer, 2001, 34, 233-241. (Pubitemid 33010799)
9. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669-676.
10. Houck, K.A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol., 1991, 5, 1806-1814.
11. Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J.C.; Abraham, J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 1991, 266, 11947-11954.
12. Fukumura, D.; Xu, L.; Chen, Y.; Gohongi, T.; Seed, B.; Jain, R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res., 2001, 61, 6020-6024.
13. Rak, J.; Yu, J.L.; Klement, G.; Kerbel, R.S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc., 2000, 5, 24-33. (Pubitemid 32044086)
14. Ferrara, N. Vascular endothelial growth factor. Trends Cardiovasc. Med., 1993, 3, 244-250.
15. Kaipainen, A.; Korhonen, J.; Mustonen, T.; van Hinsbergh, V.W.; Fang, G.H.; Dumont, D.; Breitman, M.; Alitalo, K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA, 1995, 92, 3566-3570.
16. Paavonen, K.; Puolakkainen, P.; Jussila, L.; Jahkola, T.; Alitalo, K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol., 2000, 156, 1499-1504. (Pubitemid 30646689)
17. Zebrowski, B.K.; Yano, S.; Liu, W.; Shaheen, R.M.; Hicklin, D.J.; Putnam, J.B. Jr.; Ellis, L.M. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res., 1999, 5, 3364-3368.
18. Zebrowski, B.K.; Liu, W.; Ramirez, K.; Akagi, Y.; Mills, G.B.; Ellis, L.M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol., 1999, 6, 373-378. (Pubitemid 29260800)
19. Presta, L.G.; Chen, H.; O'Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57, 4593-4599. (Pubitemid 27441066)
20. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355, 2542-2550. (Pubitemid 44917502)
21. Reck, M.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; Leighl, N.; Mezger, J.; Archer, V.; Moore, N.; Manegold, C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol., 2009, 27, 1227-1234.
22. rd; Gaudreault, J.; Damico, L.A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol., 2004, 22, 2184-2191.
23. Manegold, C.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; Leighl, N.; Mezger, J.; Archer, V.; Reck, M. A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann. Oncol., 2008, 19 (Suppl. 8), viii1 (abstr. LBA1).
24. Crinò, L.; Mezger, J.; Griesinger, F.; Zhou, C.; Reck, M. MO19390 (SAiL): safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2009, 27(15S), 417s (abstr. 8043).
25. Dowlati, A.; Gray, R.; Sandler, A.B.; Schiller, J.H.; Johnson, D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin. Cancer Res., 2008, 14, 1407-1412.
26. http://www.emea.europa.eu/pdfs/human/opinion/Avastin-12112009en.pdf accessed July 3, 2009.
27. Sandler, A.B.; Schiller, J.H.; Gray, R.; Dimery, I.; Brahmer, J.; Samant, M.; Wang, L.I.; Johnson, D.H. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J. Clin. Oncol., 2009, 27, 1405-1412.
28. Socinski, M.A.; Morris, D.E.; Stinchombe, T.E.; Halle, J.S.; Moore, D.T.; Tynan, M.T.; Siegel, M.A.; Petty, W.J.; Blackstoke, A.W.; Khandani, A.H.; Rosenman, J.G. Incorporation of bevacizumab (B) and erlotinib (E) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2008, 26(15S), 401s (abstr. 7517).
29. Wedge, S.R.; Ogilvie, D.J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J.A.; Boffey, S.J.; Valentine, P.J.; Curwen, J.O.; Musgrove, H.L.; Graham, G.A.; Hughes, G.D.; Thomas, A.P.; Stokes, E.S.E.; Curry, B.; Richmond, G.H.P.; Wadsworth, P.F.; Bigley, A.L.; Hennequin, L.F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res., 2002, 62, 4645-4655. (Pubitemid 34898591)
30. Natale, R.B.; Bodkin, D.; Govindan, R.; Sleckman, B.G.; Rizvi, N.A.; Capo, A.; Germonprè, P.; Eberhardt, W.E.; Stockman, P.K.; Kennedy, S.J; Ranson, M. Vandetanib versus gefitinib in patients with advanced non-small cell lung cancer: results from a two-part, double-blind, randomized phase II trial. J. Clin. Oncol., 2009, 27, 2523-2529.
31. Hanrahan, E.O.; Ryan, A.J.; Mann, H.; Kennedy, S.J.; Langmuir, P.; Natale, R.B.; Herbst, R.S.; Johnson, B.E.; Heymach, J.V. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin. Cancer Res., 2009, 15, 3600-3609.
32. Herbst, R.S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S.J.; Johnson, B.E. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J. Clin. Oncol., 2009, 27(18S), 807s (abstr. CRA8003).
33. De Boer, R.; Arrieta, O.; Gottfried, M.; Blackhall, F.H.; Raats, J.; Yang, C.H.; Langmuir, P.; Milenkova, T.; Read, J.; Vansteenkiste, J. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J. Clin. Oncol., 2009, 27(15S), 409s (abstr. 8010).
34. Natale, R.B.; Thongprasert, S.; Greco, F.A.; Thomas, M.; Tsai, C.M.; Sunpaweravong, P.; Ferry, D.; Langmuir, P.; Rowbottom, J.A.; Goss, G.D. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J. Clin. Oncol., 2009, 27(15S), 409s (abstr. 8009).
35. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-7109.
36. Minami, H.; Kawada, K.; Ebi, H.; Kitagawa, K.; Kim, Y.I.; Araki, K.; Mukai, H.; Tahara, M.; Nakajima, H.; Nakajima, K. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci., 2008, 99, 1492-1498. (Pubitemid 351761743)
37. Adjei, A.A.; Molina, J.R.; Hillman, S.L.; Luyun, R.F.; Reuter, N.F.; Rowland Jr, K.R.; Jett, J.R.; Mandrekar, S.J.; Schild, S.E. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J. Clin. Oncol., 2007, 25(18S), 396s (abstr. 7547).
38. Hanna, N.H.; von Pawel, J.; Reck, M.; Scagliotti, G. Carboplatin/ paclitaxel with/without sorafenib in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): Interim analysis (IA) results from a randomized phase III trial (ESCAPE). J. Thorac. Oncol., 2008, 3 (suppl.), S268 (abstr. 13).
39. Abrams, T.J.; Lee, L.B.; Murray, L.J.; Pryer, N.K.; Cherrington, J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther., 2003, 2, 471-478.
40. Mendel D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L-B.; Murray, L.I.; Carver, J.; Chan, E.; Moss, K.G.; Haznedar, J.O.; Sukbuntherng, J.; Blake, R.A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res., 2003, 9, 327-337. (Pubitemid 36109749)
41. Buckstein, R.; Meyer, R.M.; Seymour, L.; Biagi, J.; Mackay, H.; Laurie, S.; Eisenhauer, E. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr. Oncol., 2007, 14, 154-161.
42. Britten, C.D.; Kabbinavar, F.; Randolph Hecht, J.R.; Bello, C.L.; Li, J.; Baum, C.; Slamon, D. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol., 2008, 61, 515-524. (Pubitemid 350275988)
43. Roskoski Jr., R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun., 2007, 356, 323-328. (Pubitemid 46452568)
44. Socinski, M.A.; Novello, S.; Brahmer, J.R.; Rosell, R.; Sanchez, J.M.; Belani, C.P.; Govindan, R.; Atkins, J.N.; Gillenwater, H.H.; Pallares, C.; Tye, L.; Selaru, P.; Chao, R.C.; Scagliotti, G.V. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 650-656. (Pubitemid 351264362)
45. Scagliotti, G.V.; Novello, S.; Brahmer, J.R.; Rosell, R.; Sanchez, J.M.; Belani, C.P.; Govindan, R.; Atkins, J.N.; Socinski, M.A. Efficacy and safety of two sunitinib (SU) dosing schedules in previously treated, advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol., 2008, 3 (suppl. 1), S72 (abstr. 197PD).
46. Novello, S.; Abrey, L.E.; Grossi, F.; Camps, C.; Mazieres, J.; Selaru, P.; Patyna, S.; Torigoe, Y.; Chao, R.; Scagliotti, G. Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. J. Clin. Oncol., 2009, 27(15S), 426s (abstr. 8077).
47. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S.D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radiziejewski, C.; Bailey, K.; Fandl J.P.; Daly, T.; Wiegand, S.J.; Yancopoulos, G.D.; Rudge, J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA, 2002, 99, 11393-11398.
48. Dupont, J.; Schwartz, L.; Koutcher, J.; Spriggs, D.; Gordon, M.; Mendelson, D.; Murren, J.; Lucarelli, A.; Cedarbaum J. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. J. Clin. Oncol., 2004, 22(14S), 197s (abstr. 3009).
49. Dupont, J.; Rothenberg, M.L.; Spriggs, D.R.; Cedarbaum, J.M.; Furfine, E.S.; Cohen, D.P.; Dancy, I.; Lee, H.S.; Cooper, W.; Lockhart A.C. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J. Clin. Oncol., 2005, 23(16S), 199s (abstr. 3029).
50. Massarelli, E.; Miller, V.A.; Leighl, N.B.; Rosen, P.J.; Albain, K.S.; Hart, L.L.; Melnyk, O.; Sternas, L.; Ackerman, J.; Herbst, R.S. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA). J. Clin. Oncol., 2007, 25(18S), 416s (abstr. 7627).
51. Siemann, D.W.; Bibby, M.C.; Dark, G.G.; Dicker, A.P.; Eskens, F.A.; Horsman, M.R.; Marme, D.; Lorusso, P.M. Differentiation and definition of vascular-targeted terapies. Clin. Cancer Res., 2005, 11, 416-420.
52. Gotlieb, A.I. The endothelial cytoskeleton: organization in normal and regenerating endothelium. Toxicol. Pathol., 1990, 18, 603-617.
53. Watts, M.E.; Woodcock, M.; Arnold, S.; Chaplin, D.J. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res., 1997, 17, 71-75.
54. Kruczynski, A.; Poli, M.; Dossi, R.; Chazottes, E.; Berrichon, G.; Ricome, C.; Giavazzi, R.; Hill, B.T.; Taraboletti, G. Antiangiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur. J. Cancer, 2006, 42, 2821-2832.
55. Hinnen, P.; Eskens, F. Vascular disrupting agents in clinical development. Br. J. Cancer, 2007, 96, 1159-1165. (Pubitemid 46625071)
56. Beauregard, D.A.; Thelwall, P.E.; Chaplin, D.J.; Hill, S.A.; Adams, G.E.; Brindle, K.M. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br. J. Cancer, 1998, 77, 1761-1767.
57. Galbraith, S.M.; Maxwell, R.J.; Lodge, M.A.; Tozer, G.M.; Wilson, J.; Taylor, N.J.; Stirling, J.J.; Sena, L.; Padhani, A.R.; Rustin, G.J. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol., 2003, 21, 2831-2842.
58. Siemann, D.W.; Shi, W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys., 2004, 60, 1233-1240. (Pubitemid 39440810)
59. Nathan, P.D.; Judson, I.; Padhani, A.; Harris, A.; Carden, C.P.; Smythe, J.; Collins, D.; Leach, M.; Walicke, P.; Rustin, G.J. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J. Clin. Oncol., 2008, 26(15S), 165s (abstr. 3550).
60. van Heeckeren, W.J.; Bhakta, S.; Ortiz, J.; Duerk, J.; Cooney, M.M.; Dowlati, A.; McCrae, K.; Remick, S.C. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J. Clin. Oncol., 2006, 24, 1485-1488.
61. McGown, A.T.; Fox, B.W. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des., 1989, 3, 249-254.
62. Vincent, L.; Kermani, P.; Young, L.M.; Cheng, J.; Zhang, F.; Shido, K.; Lam, G.; Bompais-Vincent H.; Zhu, Z.; Hicklin, D.J.; Bohlen, P.; Chaplin, D.J.; May, C.; Rafii, S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Invest., 2005, 115, 2992-3006. (Pubitemid 41567565)
63. Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W.P.; Stratford, M.; Jesberger, J.; Rafie, N.; Overmoyer, B.; Makkar, V.; Stambler, B.; Taylor, A.; Waas, J.; Lewin, J.S.; McKrae, K.R.; Remick, S.C. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res., 2002, 62, 3408-3416.
64. Rustin, G.J.; Galbraith, S.M.; Anderson, H.; Stratford, M.; Folkes, L.K.; Sena, L.; Gumbrell, L.; Price, P.M. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol., 2003, 21, 2815-2822. (Pubitemid 46621828)
65. Stevenson, J.P.; Rosen, M.; Sun, W.; Gallagher, M.; Haller, D.G.; Vaughn, D.; Giantonio, B.; Zimmer, R.; Petros, W.P.; Stratford, M.; Chaplin, D.; Young, S.L.; Schnall, M.; O'Dwyer, P.J. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol., 2003, 21, 4428-4438.
66. Mandeville, H.C.; Goh, V.; Ng, Q.S.; Milner, J.; Saunders, M.I.; Hoskin, P.J. Volumetric perfusion CT assessment of concurrent combretastatin-A4- phosphate (CA4P) and radiotherapy (RT) in non-small cell lung cancer. J. Clin. Oncol., 2008, 26(15S), 634s (abstr. 14584).
67. Ozawa, Y.; Sugi, N.H.; Nagasu, T.; Owa, T.; Wantanabe, T.; Koyanagi, N.; Yoshino, H.; Kitoh, K.; Yoshimatsu, K. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur. J. Cancer, 2001, 37, 2275-2282. (Pubitemid 33001300)
68. Hande, K.R.; Hagey, A.; Berlin, J.; Cai, I.; Meek, K.; Kobayashi, H.; Lockhart, A.C.; Medina, D.; Sosman, J.; Gordon, G.B.; Rothenberg, M.L. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin. Cancer Res., 2006, 9, 2834-2840.
69. Mauer, A.M.; Cohen, E.E.; Ma, P.C.; Kozloff, M.F.; Schwartzberg, L.S.; Coates, A.I.; Qian, J.; Hagey, A.E.; Gordon, G.B. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 631-636. (Pubitemid 351787308)
70. Dragnev, K.H.; Rigas, J.R.; Disalvo, W.M.; Simeone, S.A.; Hagey, A.E.; Gordon, G.B.; Dmitrovsky, E. A phase I trial of ABT-751 and carboplatin (C) in patients (pts) with previously treated non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2006, 24(18S), 674s (abstr. 17098).
71. Corbett, T.H.; Bissery, M.C.; Wozniak, A.; Plowman, J.; Polin, L.; Tapazoglou, E.; Dieckman, J.; Valeriote, F. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest. New Drugs, 1986, 4, 207-220.
72. Ching, L.M.; Cao, Z.; Kieda, C.; Zwain, S.; Jameson, M.B.; Baguley, B.C. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br. J. Cancer, 2002, 86, 1937-1942. (Pubitemid 34888632)
73. McKeage, M. Phase Ib/II study od DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2006, 24(18S), 389s (abstr. 7102).
74. McKeage, M.J.; von Pawel, J.; Reck, M.; Jameson, M.B.; Rosenthal, M.A.; Sullivan, R.; Gibbs, D.; Mainwaring, P.M.; Serke, M.; Lafitte, J.J.; Chouaid, C.; Freitag, L.; Quoix, E. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br. J. Cancer, 2008, 99, 2006-2012.
75. 2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer, 2009, 65, 192-197.
76. McKeage, M.J.; Jameson, M.B. Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404). J. Clin. Oncol., 2008, 26(15S), 441s (abstr. 8072).
77. Ciardiello, F.; Bianco, R.; Damiano, V.; Fontanini, G.; Caputo, R.; Pomatico, G.; De Placido, S.; Bianco, A.R.; Mendelsohn J.; Tortora G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res., 2000, 6, 3739-3747. (Pubitemid 30694960)
78. Herbst, R.S.; Johnson, D.H.; Mininberg, E.; Carbone, D,P.; Henderson, T.; Kim, E.S.; Blumenschein Jr, G.; Lee, J.J.; Liu, D.D.; Truong, M.T.; Hong, W.K.; Tran, H.; Tsao, A.; Xie, D.; Ramies, D.A.; Mass, R.; Seshagiri, S.; Eberhard, D.A.; Kelley, S.K.; Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol., 2005, 23, 2544-2555.
79. Herbst, R.S.; O'Neill, V.J.; Fehrenbacher, L.; Belani, C.P.; Bonomi, P.D.; Hart, L.; Melnyk, O.; Ramies, D.; Lin, M.; Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol., 2007, 25, 4743-4750. (Pubitemid 350086476)
80. http://www.roche.com/investors/ir-update/inv-update-2008-11-14.htm accessed on July 1, 2009.
81. Groen, H.J.; Smit, E.F.; Dingemans, A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2007, 25(18S), 415s (abstr. 7625).
82. Miller, V.A.; Das, A.; Rossi, M. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2009, 27(15S), 407s (abstr. LBA8002).
83. Adjei, A.A.; Molina, J.R.; Mandrekar, S.J.; Marks, R.; Reid, J.R.; Croghan, G.; Hanson, L.J.; Jett, J.R.; Xia, C.; Lathia, C.; Simantov, R. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin. Cancer Res., 2007, 13, 2684-2691. (Pubitemid 46788036)
84. Duran, I.; Hotté, S.J.; Hirte, H.; Chen, E.X.; MacLean, M.; Turner, S.; Duan, L.; Pond, G.R.; Lathia, C.; Walsh, S.; Wright, J.J.; Dancey, J.; Siu, L.L. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin. Cancer Res., 2007, 15, 4849-4857. (Pubitemid 47294792)
85. Lind, J.S.; Dingemans, A.C.; Groen, H.J.; Smit, E.F. A phase II study of erlotinib and sorafenib in chemotherapy-naïve patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2009, 27(15S), 411s (abstr. 8018).
86. Gridelli, C.; Rossi, A.; Morgillo, F.; Bareschino, M.; Maione, P.; Ciardiello, F. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin. Lung Cancer, 2007, 8, 396-398. (Pubitemid 46918286)
87. Blumenschein Jr, G.R.; Robert, F.; Melnyk, O.; Wang, E.; Selaru, P.; Chao, R.; Fossella, F. Erlotinib (E) with or without sunitinib (SU) in the treatment of metastatic non-small cell lung cancer (NSCLC): A phase II study. J. Thorac. Oncol., 2008, 3 (suppl. 1), S77 (abstr. 212P).
88. Govindan, R.; Blumenschein, G.; Groen, H.J.M.; Szczesna, A.; Stausz, J.; Montesinos, J.; Chao, R.; Scagliotti, G.V. Sunitinib plus erlotinib, a novel VEGFR-EGFR co-inhibition treatment strategy in patients (pts) with metastatic non-small cell lung cancer (NSCLC). J. Thorac. Oncol., 2008, 3 (suppl. 1), S79 (abstr. 216P).
89. Herbst, R.S.; Onn, A.; Sandler, A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J. Clin. Oncol., 2005, 23, 3243-3256. (Pubitemid 46211349)
90. Bocci, G.; Man, S.; Green, S.K.; Francia, G.; Ebos, J.M.; du Manoir, J.M.; Weinerman, A.; Emmenegger, U.; Ma, L.; Thorpe, P.; Davidoff, A.; Huber, J.; Hicklin, D.J.; Kerbel, R.S. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res., 2004, 64, 6616-6625.
91. Kalka, C.; Masuda, H.; Takahashi, T.; Gordon, R.; Tepper, O.; Gravereaux, E.; Pieczek, A.; Iwaguro, H.; Hayashi, S.I.; Isner, J.M.; Asahara T. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res., 2000, 86, 1198-1202. (Pubitemid 30436658)